Curevac earns repeat recognition by lexisnexis(r) as one of the world's top innovators

Curevac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio the company holds one of the broadest intellectual property portfolios in mrna technology tÜbingen, germany and boston, ma / access newswire / february 18, 2025 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced its recognition as a top 100 global innovator in the innovation momentum 2025 report by lexisnexis®.
CVAC Ratings Summary
CVAC Quant Ranking